off label tirzepatide Weight loss: How effective is as off-label treatment? 🗞️ The latest GLP-1 monitoring

Compounded medications are not FDA-approved or reviewed before marketing for safety, effectiveness or quality

Key highlights Tirzepatide is the first dual GLP-1/GIP receptor agonist that offers stronger appetite suppression, improved glycemic control, and provides significantly greater weight loss than single receptor agonists such as semaglutide, liraglutide, and dulaglutide

using Baseline days as control: F 1,4 = 8.46, p = 0.044)

Learn more about our Healthy Weight program and discover a plan that's right for you.

If you have documented cardiovascular disease, your clinician may be able to submit the prior authorization under the cardiovascular indication rather than the weight management indication